MILAN ( –  ArchiMed’s bid for Medtech and Pharma services provider Bomi Group is subject to a number of conditions, notably that 90% of all shares be tendered (the threshold for delisting the firm), but it already has the support of all major shareholders of record. If successful, it will be the first transaction for ArchiMed’s new mid-market buy-and-build fund, MED Platform I (€800 million target size). The bid for Bomi Group translates into a per share offer of € 4.00, as well as an offer of € 4,000 for each of the Company’s convertible bonds. All investors currently of record with stakes of more than 5 percent have committed to selling their full shareholdings in Bomi Group to MED Platform I. This shareholders group encompasses the Ruini family’s subsidiaries (as well as individual family members), Quaestio Capital Management Società di Gestione del Risparmio S.p.A. (on behalf of the fund Quaestio Italian Growth Fund) and First Capital S.p.A.. The three respectively own approximately 50.4% (including subsidiaries and the Ruini family members individually), 12.4% and 5.6% of Bomi Group. If the bid is successful, Bomi Group’s management team and Chief Executive, Marco Ruini, will remain in office, with the latter reinvesting more than 40% of his proceeds from the sale back into the company for a 5 percent stake. Upon the deal’s completion, ArchiMed Partner André-Michel Ballester will become Bomi’s new Chairman.

“In addition to its sector expertise and industry networks, ArchiMed intends to make significant investments, allowing Bomi Group to expand more rapidly, both organically and through acquisitions. The entry of such a strong and specialized stakeholder represents clear added value when it comes to the fulfilment of our ambitious growth targets,” says Bomi Group Chief Executive Marco Ruini.